Filtered By:
Vaccination: Meningitis Vaccine
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 9804 results found since Jan 2013.
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Surveillance for certain health behaviors among States and selected local areas - United States, 2010.
This report presents results for 2010 for all 50 states, the District of Columbia, the Commonwealth of Puerto Rico, Guam, the U.S. Virgin Islands, 192 MMSAs, and 302 counties. Results: In 2010, the estimated prevalence of high-risk health behaviors, chronic diseases and conditions, access to health care, and use of preventive health services varied substantially by state and territory, MMSA, and county. In the following summary of results, each set of proportions refers to the range of estimated prevalence for the disease, condition, or behaviors, as reported by survey respondents. Adults reporting good or better health: 6...
Source: MMWR Surveill Summ - May 31, 2013 Category: Epidemiology Authors: Xu F, Town M, Balluz LS, Bartoli WP, Murphy W, Chowdhury PP, Garvin WS, Pierannunzi C, Zhong Y, Salandy SW, Jones CK, Crawford CA, Division of Behavioral Surveillance, Office of Surveillance, Epidemiology, and Laboratory Services, CDC Tags: MMWR Surveill Summ Source Type: research
IJERPH, Vol. 16, Pages 265: Parental Knowledge about Meningococcal Disease and Vaccination Uptake among 0 –5 years Old Polish Children
IJERPH, Vol. 16, Pages 265: Parental Knowledge about Meningococcal Disease and Vaccination Uptake among 0–5 years Old Polish Children
International Journal of Environmental Research and Public Health doi: 10.3390/ijerph16020265
Authors:
Marzena Drozd-Dąbrowska
Katarzyna Topczewska
Marcin Korzeń
Anna Sałacka
Maria Ganczak
In Poland, in addition to mandatory, free of charge vaccines, listed in the national immunization schedule, numerous self-paid vaccinations are recommended, including meningococcal vaccination (MV). To assess MV uptake among ≤5-year-old children and to evaluate parental know...
Source: International Journal of Environmental Research and Public Health - January 18, 2019 Category: Environmental Health Authors: Marzena Drozd-D ąbrowska Katarzyna Topczewska Marcin Korze ń Anna Sa łacka Maria Ganczak Tags: Article Source Type: research
Influenza A Virus Infection Predisposes Hosts to Secondary Infection with Different Streptococcus pneumoniae Serotypes with Similar Outcome but Serotype-Specific Manifestation Host Response and Inflammation
Influenza A virus (IAV) and Streptococcus pneumoniae are major causes of respiratory tract infections, particularly during coinfection. The synergism between these two pathogens is characterized by a complex network of dysregulated immune responses, some of which last until recovery following IAV infection. Despite the high serotype diversity of S. pneumoniae and the serotype replacement observed since the introduction of conjugate vaccines, little is known about pneumococcal strain dependency in the enhanced susceptibility to severe secondary S. pneumoniae infection following IAV infection. Thus, we studied how preinfecti...
Source: Infection and Immunity - November 17, 2016 Category: Infectious Diseases Authors: Sharma-Chawla, N., Sender, V., Kershaw, O., Gruber, A. D., Volckmar, J., Henriques-Normark, B., Stegemann-Koniszewski, S., Bruder, D. Tags: Host Response and Inflammation Source Type: research
Pneumococcal disease in the Arabian Gulf: Recognizing the challenge and moving toward a solution
Summary: Pneumococcal disease has substantial incidence, morbidity and mortality in older adults. Decreased birth rates and longer lifespans indicate that the global population is aging, although rates of aging differ between countries . In 2010, the proportion of the population aged>60 years in the general Arab Region was 7%, and this proportion is expected to rise to 19% by 2050 for the region as a whole ; the United Nations estimates for the individual countries of the Arabian Gulf by 2050 are 25.7%, 24.9%, 20.7%, 26.7% and 10.5% in the Kuwait, Bahrain, Qatar, United Arab Emirates (UAE) and Oman, respectively, which are...
Source: Journal of Infection and Public Health - August 2, 2013 Category: Global & Universal Authors: Charles Feldman, Emad Abdulkarim, Fatma Alattar, Faryal Al Lawati, Hisham Al Khatib, Muna Al Maslamani, Idris Al Obaidani, Mosaab Al Salah, Mohamed Farghaly, Entesar H. Husain, Eiman Mokadas Tags: Review Source Type: research
Molecular characterization of penicillin non-susceptible Streptococcus pneumoniae isolated before and after pneumococcal conjugate vaccine implementation in Casablanca, Morocco
Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide, especially among children and the elderly. The ability to effectively treat pneumococcal infection has b...
Source: Annals of Clinical Microbiology and Antimicrobials - April 4, 2017 Category: Microbiology Authors: Idrissa Diawara, Abouddihaj Barguigua, Khalid Katfy, Kaotar Nayme, Houria Belabbes, Mohammed Timinouni, Khalid Zerouali and Naima Elmdaghri Source Type: research
Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy
Clinical guidelines recommend pneumococcal and tetanus vaccinations in patients with rheumatoid arthritis (RA). Baricitinib is an oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor and is approved for the tr...
Source: Arthritis Research and Therapy - April 18, 2019 Category: Rheumatology Authors: Kevin L. Winthrop, Clifton O. Bingham III, Wendy J. Komocsar, John Bradley, Maher Issa, Rena Klar and Cynthia E. Kartman Tags: Research article Source Type: research
Whole-genome sequencing and characterization of an antibiotic resistant Neisseria meningitidis B isolate from a military unit in Vietnam
Invasive meningococcal disease (IMD) persists in military units in Vietnam despite the availability of antibiotics and vaccines. A hindrance to reducing the incidence of IMD in Vietnam is a lack of molecular d...
Source: Annals of Clinical Microbiology and Antimicrobials - May 6, 2019 Category: Microbiology Authors: Thach Xuan Tran, Trang Thu Le, Long Phi Trieu, Christopher M. Austin, Dong Van Quyen and Huong Minh Nguyen Tags: Research Source Type: research
Current developments and trends in childhood immunization
Abstract: In this paper we highlight several instances in which there is potential for novel utilization in the near future of relatively recently licenced vaccines, vaccines approaching licensure or vaccines already in established use. Specifically we discuss the potential for universal seasonal influenza immunization and the arrival of live attenuated intranasal vaccine which was licenced for use in children aged 2–17 years in Europe in 2010, the potential use of live oral rotavirus vaccines for infants, two of which have been available in Europe since 2006, pertussis, which despite availability and widespread use thro...
Source: Paediatrics and Child Health - March 1, 2013 Category: Pediatrics Authors: Valtyr S. Thors, Robin D. Marlow, Adam Finn Tags: Symposium: Immunity and Infection Source Type: research
A166: Evaluation of Quality Indicators and Disease Damage in Childhood‐Onset Systemic Lupus Erythematosus Patients
Conclusion:Baseline application of proposed quality indicators in our cSLE population is varied ranging from 17.3% to 94.6%. This data is important to standardize care and target certain domains of disease management for improvement such as education and vaccination. The three most common areas of damage in our study may be related to corticosteroid use. This knowledge of organ‐specific damage is important to help identify at‐risk patients to optimize care and focus quality improvement efforts.
Source: Arthritis and Rheumatism - March 27, 2014 Category: Rheumatology Authors: Julia G. Harris, Kristyn I. Maletta, Evelyn M. Kuhn, Judyann C. Olson Tags: Poster Breakout Session I: Quality, Health Services and Education Research Thursday, April 3, 2014; 4:00–4:30 PM Source Type: research
Mucosal Immunization with the Live Attenuated Vaccine SPY1 Induces Humoral and Th2-Th17-Regulatory T Cell Cellular Immunity and Protects against Pneumococcal Infection Microbial Immunity and Vaccines
Mucosal immunization with attenuated vaccine can protect against pneumococcal invasion infection, but the mechanism was unknown. Our study found that mucosal delivery with the live attenuated SPY1 vaccine strain can confer T cell- and B cell-dependent protection against pneumococcal colonization and invasive infection; yet it is still unclear which cell subsets contribute to the protection, and their roles in pneumococcal colonization and invasion remain elusive. Adoptive transfer of anti-SPY1 antibody conferred protection to naive μMT mice, and immune T cells were indispensable to protection examined in nude mice. A cr...
Source: Infection and Immunity - December 16, 2014 Category: Infectious Diseases Authors: Xu, X., Wang, H., Liu, Y., Wang, Y., Zeng, L., Wu, K., Wang, J., Ma, F., Xu, W., Yin, Y., Zhang, X. Tags: Microbial Immunity and Vaccines Source Type: research
Recombinant Protein Truncation Strategy for Inducing Bactericidal Antibodies to the Macrophage Infectivity Potentiator Protein of Neisseria meningitidis and Circumventing Potential Cross-Reactivity with Human FK506-Binding Proteins Microbial Immunity and Vaccines
A recombinant macrophage infectivity potentiator (rMIP) protein of Neisseria meningitidis induces significant serum bactericidal antibody production in mice and is a candidate meningococcal vaccine antigen. However, bioinformatics analysis of MIP showed some amino acid sequence similarity to human FK506-binding proteins (FKBPs) in residues 166 to 252 located in the globular domain of the protein. To circumvent the potential concern over generating antibodies that could recognize human proteins, we immunized mice with recombinant truncated type I rMIP proteins that lacked the globular domain and the signal leader peptide (L...
Source: Infection and Immunity - January 14, 2015 Category: Infectious Diseases Authors: Bielecka, M. K., Devos, N., Gilbert, M., Hung, M.-C., Weynants, V., Heckels, J. E., Christodoulides, M. Tags: Microbial Immunity and Vaccines Source Type: research
Binding of Complement Factor H to PorB3 and NspA Enhances Resistance of Neisseria meningitidis to Anti-Factor H Binding Protein Bactericidal Activity Microbial Immunity and Vaccines
Among 25 serogroup B Neisseria meningitidis clinical isolates, we identified four (16%) with high factor H binding protein (FHbp) expression that were resistant to complement-mediated bactericidal activity of sera from mice immunized with recombinant FHbp vaccines. Two of the four isolates had evidence of human FH-dependent complement downregulation independent of FHbp. Since alternative complement pathway recruitment is critical for anti-FHbp bactericidal activity, we hypothesized that in these two isolates binding of FH to ligands other than FHbp contributes to anti-FHbp bactericidal resistance. Knocking out NspA, a know...
Source: Infection and Immunity - March 17, 2015 Category: Infectious Diseases Authors: Giuntini, S., Pajon, R., Ram, S., Granoff, D. M. Tags: Microbial Immunity and Vaccines Source Type: research
Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets Microbial Immunity and Vaccines
The role of CD19+ CD5+ and CD19+ CD5– B cell subpopulations in the antibody response to pneumococcal capsular polysaccharides (caps-PSs) is controversial. In the present study, we evaluated the role of human CD19+ CD5+ and CD19+ CD5– cell populations in the serotype-specific antibody response to caps-PS. After vaccination of 5 healthy human adults with Pneumovax (23-valent pneumococcal polysaccharide vaccine [PPV23]), IgG anti-caps-PS serotype 4 antibody-producing cells resided mainly in the CD19+ CD5– B cell subset, as assessed by enzyme-linked immunosorbent spot (ELISpot) analysis. Moreover, in a humani...
Source: Infection and Immunity - June 15, 2015 Category: Infectious Diseases Authors: Moens, L., Verbinnen, B., Covens, K., Wuyts, G., Johnson, M., Roalfe, L., Goldblatt, D., Meyts, I., Bossuyt, X. Tags: Microbial Immunity and Vaccines Source Type: research
Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice Microbial Immunity and Vaccines
Neisserial surface protein A (NspA) is a highly conserved outer membrane protein previously investigated as a meningococcal vaccine candidate. Despite eliciting serum bactericidal activity in mice, a recombinant NspA vaccine failed to elicit serum bactericidal antibodies in a phase 1 clinical trial in humans. The discordant results may be explained by the recent discovery that NspA is a human-specific ligand of the complement inhibitor factor H (FH). Therefore, in humans but not mice, NspA would be expected to form a complex with FH, which could impair human anti-NspA protective antibody responses. To investigate this ques...
Source: Infection and Immunity - January 25, 2016 Category: Infectious Diseases Authors: Lujan, E., Pajon, R., Granoff, D. M. Tags: Microbial Immunity and Vaccines Source Type: research
